>

  • Showcases
  • >
  • UEGW 2020 | Ozanimod maintains remission in patients with ulcerative colitis

UEGW 2020 | Ozanimod maintains remission in patients with ulcerative colitis

Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.

Showcase

MEET THE SENIOR TEAM

Lynda Williams

medwireNews Deputy Bureau Chief

Related Showcases

|